Literature DB >> 12899609

Severe neutropenia and thrombocytopenia associated with infliximab.

Francesc Vidal1, Ramón Fontova, Cristóbal Richart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12899609     DOI： 10.7326/0003-4819-139-3-200308050-00021-w4

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  13 in total

1.  Infliximab and serious hematologic events.

Authors:  Cynthia Phelan; Eric Wooltorton
Journal:  CMAJ       Date:  2004-10-26       Impact factor: 8.262

2.  Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.

Authors:  Athina Theodoridou; Charalambos Kartsios; Efthalia Yiannaki; Dimitra Markala; Lucas Settas
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

3.  Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.

Authors:  S Rajakulendran; K Gadsby; D Allen; S O'Reilly; C Deighton
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

4.  Combination of infliximab with thiopurines significantly reduces white cell and neutrophil counts in inflammatory bowel disease patients.

Authors:  V Parihar; O Maceneaney; S Maguire; C Garry; M O'Sullivan; M Kennedy; K Safaya; C Smyth; R Farrell
Journal:  Ir J Med Sci       Date:  2016-05-30       Impact factor: 1.568

Review 5.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

6.  Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges.

Authors:  E Montané; M Sallés; A Barriocanal; E Riera; J Costa; X Tena
Journal:  Clin Rheumatol       Date:  2006-10-10       Impact factor: 2.980

7.  Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation.

Authors:  Mehdi Hamadani; Craig C Hofmeister; Buffy Jansak; Gary Phillips; Patrick Elder; William Blum; Sam Penza; Thomas S Lin; Rebecca Klisovic; Guido Marcucci; Sherif S Farag; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2008-07       Impact factor: 5.742

8.  Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years' drug survival.

Authors:  Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen
Journal:  Rheumatol Int       Date:  2009-10-10       Impact factor: 2.631

Review 9.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

10.  Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients.

Authors:  L R Coulthard; J Geiler; R J Mathews; L D Church; L J Dickie; D L Cooper; C Wong; S Savic; D Bryer; M H Buch; P Emery; A W Morgan; M F McDermott
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.